{"id":"risperdal-reminyl","safety":{"commonSideEffects":[{"rate":"10–20","effect":"Extrapyramidal symptoms (tremor, rigidity, akathisia)"},{"rate":"15–25","effect":"Weight gain"},{"rate":"10–15","effect":"Hyperprolactinemia"},{"rate":"10–20","effect":"Sedation"},{"rate":"10–15","effect":"Nausea (Reminyl)"},{"rate":"10–15","effect":"Diarrhea (Reminyl)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Risperdal reduces dopamine and serotonin signaling to treat psychotic symptoms and mood disturbances in schizophrenia and bipolar disorder. Reminyl inhibits acetylcholinesterase to elevate acetylcholine concentrations, improving cognitive function in Alzheimer's disease. These are two distinct drugs with different mechanisms and therapeutic targets.","oneSentence":"Risperdal is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors, while Reminyl (galantamine) is a cholinesterase inhibitor that increases acetylcholine levels in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:20.445Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia (Risperdal)"},{"name":"Bipolar disorder (Risperdal)"},{"name":"Irritability associated with autism spectrum disorder (Risperdal)"},{"name":"Mild to moderate Alzheimer's disease (Reminyl)"}]},"trialDetails":[{"nctId":"NCT00626613","phase":"PHASE4","title":"The Relationship Between Risperdal Treatment and Quality of Life in Patients With Alzheimer's Disease and Behavioural and Psychological Symptoms of Dementia (BPSD)","status":"UNKNOWN","sponsor":"Jinan Mental Hospital","startDate":"","conditions":"Dementia, Alzheimer's Disease","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Risperdal,reminyl","genericName":"Risperdal,reminyl","companyName":"Jinan Mental Hospital","companyId":"jinan-mental-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Risperdal is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors, while Reminyl (galantamine) is a cholinesterase inhibitor that increases acetylcholine levels in the brain. Used for Schizophrenia (Risperdal), Bipolar disorder (Risperdal), Irritability associated with autism spectrum disorder (Risperdal).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}